Alzheimer's brain change measured in humans

June 12, 2013, Washington University School of Medicine
Mutations in PSEN1 and PSEN2, the enzymatic components of gamma-secretase, increase the rate of production of Aβ42 peptides (yellow arrow). The soluble Aβ peptides may be irreversibly lost (red arrows) by retrograde transport across the blood brain barrier, transfer into the CSF, or by degradation within the brain. The soluble Aβ peptides may also be deposited into plaques, either directly or via a reversible exchange process (blue arrows). The reversible exchange process is kinetically distinct from the irreversible losses. Credit: Randall Bateman/Familial Adult Children Study (5P01AG026276-S1)

Scientists at Washington University School of Medicine in St. Louis have measured a significant and potentially pivotal difference between the brains of patients with an inherited form of Alzheimer's disease and healthy family members who do not carry a mutation for the disease.

Researchers have known that amyloid beta, a , builds up into plaques in the brains of Alzheimer's patients. They believe the plaques cause the and other that characterize the disease. Normal produces different forms of amyloid beta.

The new study shows that research participants with that cause early-onset Alzheimer's make about 20 percent more of a specific form of amyloid beta – known as amyloid beta 42 – than family members who do not have the Alzheimer's mutation.

Scientists found another, more surprising difference linked to amyloid beta 42 in mutation carriers: signs that amyloid beta 42 drops out of the cerebrospinal fluid much more quickly than other forms of amyloid beta. This may be because amyloid beta 42 is being deposited on .

"These results indicate how much we should target amyloid beta 42 with Alzheimer's drugs," said Randall Bateman, MD, the Charles F. and Joanne Knight Distinguished Professor of . "We are hopeful that this and other research will lead to preventive therapies to delay or even possibly prevent Alzheimer's disease."

The study appears June 12 in Science Translational Medicine.

In addition to helping develop treatments for inherited Alzheimer's, investigations of these conditions have helped scientists lay the groundwork for advances in treatment of the much more common sporadic forms of the disease.

Three forms account for most of the amyloid beta found in the cerebrospinal fluid: amyloid beta 38, 40 and 42. Earlier studies of the after death and using animal research had suggested that amyloid beta 42 was the most important contributor to Alzheimer's. The new study not only confirms this connection but also quantifies overproduction of amyloid beta 42 for the first time in living human brains.

Bateman, who co-developed a technique that measures the rate at which amyloid beta is produced and cleared from the , contacted several Washington University colleagues to see if they could develop a way to analyze the types of amyloid beta being produced in the brain.

Bateman, metabolism expert Bruce Patterson, PhD, and biomedical engineer Donald Elbert, PhD, created a new mathematical model to describe the production and clearance of amyloid beta.

The scientists applied the model to data from 11 research participants with Alzheimer's mutations and 12 related family members who did not have the genetic errors that cause Alzheimer's. The model let the scientists compare the production rates of the protein's different forms, revealing an increase in amyloid beta 42 production in subjects with an Alzheimer's gene.

"Working in isolation, any one of us would likely have gotten the wrong answer, or no answer," Elbert said. "Bringing our different skill sets together let us tackle a very complex physiological problem."

Scientists are testing the new model on data from approximately 100 Alzheimer's patients.

"We hope that our new insights about the production and clearance of amyloid beta proteins will pave the way for future studies aimed at understanding and altering the metabolic processes that underlie this devastating disease," Patterson said.

Explore further: New perspective needed for role of major Alzheimer's gene

More information: "Increased in Vivo Amyloid-β42 Production, Exchange, and Irreversible Loss in Presenilin Mutations Carriers," by R. Potter et al. Science Translational Medicine, 2013.

Related Stories

New perspective needed for role of major Alzheimer's gene

May 7, 2013
(Medical Xpress)—Scientists' picture of how a gene strongly linked to Alzheimer's disease harms the brain may have to be revised, researchers at Washington University School of Medicine in St. Louis have found.

Bursts of brain activity may protect against Alzheimer's disease

April 18, 2013
Evidence indicates that the accumulation of amyloid-beta proteins, which form the plaques found in the brains of Alzheimer's patients, is critical for the development of Alzheimer's disease, which impacts 5.4 million Americans. ...

Amyloid beta in the brain of individuals with Alzheimer's disease

March 30, 2012
While there may not be a consensus whether deposition of amyloid beta contributes to Alzheimer's disease or is a consequence of it, there is agreement that something else is promoting the process. Other proteins are often ...

A new strategy required in the search for Alzheimer's drugs?

May 24, 2013
In the search for medication against Alzheimer's disease, scientists have focused – among other factors – on drugs that can break down Amyloid beta (A-beta). After all, it is the accumulation of A-beta that causes the ...

Genetic markers ID second Alzheimer's pathway

April 4, 2013
Researchers at Washington University School of Medicine in St. Louis have identified a new set of genetic markers for Alzheimer's that point to a second pathway through which the disease develops.

A molecular chain reaction in Alzheimer's disease

May 29, 2013
Researchers at Lund University in Sweden have identified the molecular mechanism behind the transformation of one of the components in Alzheimer's disease. They identified the crucial step leading to formations that kill ...

Recommended for you

Largest study of its kind finds alcohol use biggest risk factor for dementia

February 21, 2018
Alcohol use disorders are the most important preventable risk factors for the onset of all types of dementia, especially early-onset dementia. This according to a nationwide observational study, published in The Lancet Public ...

Data detectives shift suspicions in Alzheimer's to inside villain

February 20, 2018
The mass pursuit of a conspicuous suspect in Alzheimer's disease may have encumbered research success for decades. Now, a new data analysis that has untangled evidence amassed in years of Alzheimer's studies encourages researchers ...

Not being aware of memory problems predicts onset of Alzheimer's disease

February 15, 2018
Doctors who work with individuals at risk of developing dementia have long suspected that patients who do not realize they experience memory problems are at greater risk of seeing their condition worsen in a short time frame, ...

Researchers successfully reverse Alzheimer's disease in mouse model

February 14, 2018
A team of researchers from the Cleveland Clinic Lerner Research Institute have found that gradually depleting an enzyme called BACE1 completely reverses the formation of amyloid plaques in the brains of mice with Alzheimer's ...

Poor fitness linked to weaker brain fiber, higher dementia risk

February 14, 2018
Scientists have more evidence that exercise improves brain health and could be a lifesaving ingredient that prevents Alzheimer's disease.

Compound prevents neurological damage, shows cognitive benefits in mouse model of Alzheimer's disease

February 7, 2018
The supplement nicotinamide riboside (NR) – a form of vitamin B3 – prevented neurological damage and improved cognitive and physical function in a new mouse model of Alzheimer's disease. The results of the study, conducted ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.